logo
Plus   Neg
Share
Email

Stock Alert: Axsome Therapeutics Up 25% As Alzheimer's Drug Achieves Main Goal

Shares of Axsome Therapeutics, Inc. (AXSM) surged over 25% on Monday morning after the clinical-stage biopharmaceutical company's lead investigational drug for Alzheimer's disease agitation achieved positive results in a study.

AXSM is currently trading at $96.89, up $20.49 or 26.82%, on the Nasdaq.

Axsome Therapeutics announced that its investigational drug AXS-05 met the primary endpoint in the Phase 2/3 trial. The drug rapidly, substantially, and significantly improved agitation in patients with Alzheimer's disease as compared to placebo.

The study conducted on 366 Alzheimer's disease patients.

There are currently no FDA-approved treatments for Alzheimer's disease agitation. Alzheimer's disease is the most common form of dementia and is characterized by cognitive decline, and behavioral and psychological symptoms including agitation. Agitation is observed in up to 70% of patients with Alzheimer's disease.

AXS-05 has been granted FDA Fast Track designation for the treatment of Alzheimer's disease agitation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT